Your browser doesn't support javascript.
loading
Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity.
Domínguez-Ortega, J; Luna-Porta, J A; Olaguibel, J M; Barranco, P; Arismendi, E; Barroso, B; Betancor, D; Bobolea, I; Caballero, M L; Cárdaba, B; Cruz, M J; Curto, E; González-Barcala, F J; Losantos-García, I; Martínez-Rivera, C; Mendez-Brea, P; Mullol, J; Muñoz, X; Picado, C; Plaza, V; Del Pozo, V; Rial, M J; Sastre, J; Soto, L; Valero, A; Valverde-Monge, M; Quirce, S.
Afiliación
  • Domínguez-Ortega J; Department of Allergy, La Paz University Hospital, Madrid, Spain.
  • Luna-Porta JA; Institute for Health Research IdiPAZ, Madrid, Spain.
  • Olaguibel JM; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Barranco P; Department of Allergy, La Paz University Hospital, Madrid, Spain.
  • Arismendi E; Institute for Health Research IdiPAZ, Madrid, Spain.
  • Barroso B; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Betancor D; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Bobolea I; Severe Asthma Unit, Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.
  • Caballero ML; Department of Allergy, La Paz University Hospital, Madrid, Spain.
  • Cárdaba B; Institute for Health Research IdiPAZ, Madrid, Spain.
  • Cruz MJ; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Curto E; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • González-Barcala FJ; Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain.
  • Losantos-García I; Universitat de Barcelona, Barcelona, Spain.
  • Martínez-Rivera C; Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain.
  • Mendez-Brea P; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Mullol J; Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Muñoz X; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Picado C; Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Plaza V; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Del Pozo V; Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain.
  • Rial MJ; Universitat de Barcelona, Barcelona, Spain.
  • Sastre J; Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain.
  • Soto L; Department of Allergy, La Paz University Hospital, Madrid, Spain.
  • Valero A; Institute for Health Research IdiPAZ, Madrid, Spain.
  • Valverde-Monge M; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Quirce S; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
J Investig Allergol Clin Immunol ; 33(4): 281-288, 2023 Jul 27.
Article en En | MEDLINE | ID: mdl-35503227
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Comorbidities can influence asthma control and promote asthma exacerbations (AEs). However, the impact of multimorbidity in AEs, assessed based on long-term follow-up of patients with asthma of different degrees of severity, has received little attention in real-life conditions. To describe the epidemiological and clinical characteristics and predictors of AEs in patients who had presented at least 1 AE in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort.

METHODS:

The work-up included a detailed clinical examination, pulmonary function testing, fractional exhaled nitric oxide (FeNO), blood counts, induced sputum, skin prick-tests, asthma questionnaires, and assessment of multimorbidity. The number of moderate-severe AEs in the preceding year was registered for each patient.

RESULTS:

The study population comprised 486 patients with asthma (23.7% mild, 35% moderate, 41.3% severe). Disease remained uncontrolled in 41.9%, and 47.3% presented ≥1 moderate-severe AE, with a mean (SD) annual exacerbation rate of 0.47 (0.91) vs 2.11 (2.82) in mild and severe asthma, respectively. Comorbidity was detected in 56.4% (66.6% among those with severe asthma). Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidemia, and hypertension were significantly associated with AEs. No associations were found for FeNO, blood eosinophils, or total serum IgE. Sputum eosinophilia and a high-T2 inflammatory pattern were significantly associated with AEs. Multivariable regression analysis showed a significant association with asthma severity, uncontrolled disease, and low prebronchodilator FEV1/FVC.

CONCLUSION:

Our study revealed a high frequency of AE in the MEGA cohort. This was strongly associated with multimorbidity, asthma severity, poor asthma control, airflow obstruction, higher sputum eosinophils, and a very high-T2 inflammatory pattern.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Eosinofilia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Eosinofilia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España